GlassScriptPhysician profile
Leat Mechlovitz
NPI 1780926790
$1,438.81
in general payments reported to CMS, 2019-2025
12 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.39 · 2020: $148 · 2021: $75.19 · 2022: $114 · 2023: $516 · 2024: $404 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921 · Education: $99.99 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.35 |
| Education | $99.99 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $476.94 | 2023-2025 | Veozah |
| Organon LLC | $234.86 | 2022-2025 | Nexplanon |
| Abbvie INC. | $192.64 | 2020-2023 | |
| Mayne Pharma Commercial LLC | $142.53 | 2021-2023 | |
| Coopersurgical, INC. | $119.65 | 2020-2024 | Paragard T 380a, Summit Doppler, Paragard T 380a |
| Evofem Biosciences, INC. | $107.82 | 2021-2024 | Phexxi |
| Covidien LP | $34.47 | 2019 | |
| Merck Sharp & Dohme LLC | $31.19 | 2024 | Gardasil, Gardasil 9 |
| Avion Pharmaceuticals | $28.79 | 2021 | |
| Millicent US INC | $24.90 | 2024 | Femring, Intrarosa |
| Exeltis, USA INC. | $24.10 | 2024 | Slynd |
| Therapeuticsmd, INC. | $20.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leat Mechlovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.